Table 2.
Demographic and clinical characteristics of melanoma patients.
| Case | Sex | Age (Years) | Stage a | BRAF STATUS | Previous Therapy | Targeted Therapy c | BR d | TTF e (Months) |
|---|---|---|---|---|---|---|---|---|
| 1 | M | 46 | III–IV | MUT | None | ENCO+BIN | PD | 16.90 |
| 2 | M | 42 | IV | MUT | None | VEMU | PD | 20.83 |
| 3 | F | 50 | IV | MUT | None | DAB | PD | 9.60 |
| 4 | M | 59 | IV | MUT | None | VEMU | PD | 18.47 |
| 5 | M | 61 | III/IV | MUT | Dacarbazine | VEMU | PD | 18.47 |
| 6 | M | 48 | NA | MUT | Radiotherapy | VEMU | PR | 73.77 |
| 7 | F | 56 | IV | MUT | None | VEMU | PD | 7.20 |
| 8 | F | 50 | III/IV | MUT | None | DAB | PD | 15.17 |
| 9 | M | 48 | NA | MUT | Radiotherapy | VEMU | PR | 73.77 |
| 10 | M | 77 | III–IV | MUT | None | DAB + TRAM | PR | 43.53 |
| 11 | F | 86 | IV | MUT | None | DAB + TRAM | SD | 37.23 |
| 12 | F | 70 | IV | MUT | None | VEMU + COBI | PR | 20.33 |
| 13 | F | 67 | III/IV | MUT | None | VEMU + COBI | CR | 25.17 |
| 14 | F | 45 | NA | MUT | None | DAB + TRAM | PR | 21.93 |
| 15 | M | 65 | IV | MUT | None | DAB + TRAM | PR | 13.43 |
| 16 | M | 47 | III/IV | MUT | None | VEMU + COBI | PR | 11.53 |
a Stage at first serum collection (i.e., T0); c ENCO, encorafenib. BIN, Binimetinib. DAB, dabrafenib. TRAM, trametinib. VEMU, vemurafenib, COBI, cobimetinib; d Best response at last tumor assessment according to RECIST 1.1 criteria: PR, partial response; SD, stable disease; PD, progressive disease, CR, complete response; e TTF, time to treatment failure.